Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

GMAB – Genmab A/S

Genmab A/S
GMAB
$22.11
Name : Genmab A/S
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $13,751,359,488.00
EPSttm : 1.7
finviz dynamic chart for GMAB
Genmab A/S
$22.11
1.38%
$0.3

Float Short %

0.45

Margin Of Safety %

34

Put/Call OI Ratio

1.03

EPS Next Q Diff

0.12

EPS Last/This Y

-0.36

EPS This/Next Y

0.3

Price

21.81

Target Price

30.73

Analyst Recom

1.75

Performance Q

-8.01

Relative Volume

0.44

Beta

0.95

Ticker: GMAB




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07GMAB20.580.586.0017803
2025-05-08GMAB19.420.583.0017802
2025-05-09GMAB19.370.59999.9917864
2025-05-12GMAB19.950.5878.0017842
2025-05-13GMAB19.320.5862.0217828
2025-05-14GMAB19.080.82102.5020622
2025-05-15GMAB19.660.820.1320654
2025-05-16GMAB19.880.8253.9020641
2025-05-19GMAB20.171.550.033512
2025-05-20GMAB20.341.551.913516
2025-05-21GMAB20.511.54100.103523
2025-05-22GMAB21.011.180.083040
2025-05-23GMAB20.811.170.003051
2025-05-27GMAB21.271.164.003062
2025-05-28GMAB21.21.161.503066
2025-05-29GMAB21.341.160.003068
2025-05-30GMAB20.971.161.333068
2025-06-02GMAB21.771.160.193073
2025-06-03GMAB21.351.027.333335
2025-06-04GMAB21.781.031.763361
2025-06-05GMAB21.81.031.363395
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07GMAB20.60-21.4-99.31.38
2025-05-08GMAB19.42-21.4-164.31.38
2025-05-09GMAB19.38-21.4-72.31.38
2025-05-12GMAB19.93-21.4-16.01.38
2025-05-13GMAB19.31-21.4-95.71.38
2025-05-14GMAB19.0822.6353.41.36
2025-05-15GMAB19.6622.615.71.36
2025-05-16GMAB19.8830.236.31.57
2025-05-19GMAB20.1830.244.31.57
2025-05-20GMAB20.3330.257.51.57
2025-05-21GMAB20.5130.222.01.57
2025-05-22GMAB21.0218.082.61.40
2025-05-23GMAB20.8018.0-14.41.40
2025-05-27GMAB21.285.974.31.34
2025-05-28GMAB21.215.923.21.34
2025-05-29GMAB21.345.991.01.34
2025-05-30GMAB20.955.962.21.34
2025-06-02GMAB21.775.980.01.34
2025-06-03GMAB21.355.945.61.34
2025-06-04GMAB21.775.964.61.34
2025-06-05GMAB21.815.926.81.34
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07GMAB00.690.33
2025-05-08GMAB00.690.33
2025-05-09GMAB00.690.33
2025-05-12GMAB00.670.39
2025-05-13GMAB00.670.39
2025-05-14GMAB00.670.39
2025-05-15GMAB00.670.39
2025-05-16GMAB00.670.39
2025-05-19GMAB0-0.020.39
2025-05-20GMAB0-0.020.39
2025-05-21GMAB0-0.020.39
2025-05-22GMAB0-0.020.39
2025-05-23GMAB0-0.020.39
2025-05-27GMAB0-0.080
2025-05-28GMAB0-0.080.45
2025-05-29GMAB0-0.080.45
2025-05-30GMAB0-0.080.45
2025-06-02GMAB0-0.100.45
2025-06-03GMAB0-0.100.45
2025-06-04GMAB0-0.100.45
2025-06-05GMAB0-0.100.45
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.31

Avg. EPS Est. Current Quarter

0.34

Avg. EPS Est. Next Quarter

0.43

Insider Transactions

Institutional Transactions

-0.1

Beta

0.95

Average Sales Estimate Current Quarter

5951

Average Sales Estimate Next Quarter

6288

Fair Value

29.24

Quality Score

100

Growth Score

100

Sentiment Score

59

Actual DrawDown %

55.6

Max Drawdown 5-Year %

-63.1

Target Price

30.73

P/E

12.37

Forward P/E

12.21

PEG

1.35

P/S

4.15

P/B

2.62

P/Free Cash Flow

11.51

EPS

1.76

Average EPS Est. Cur. Y​

1.34

EPS Next Y. (Est.)

1.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.11

Relative Volume

0.44

Return on Equity vs Sector %

-3.3

Return on Equity vs Industry %

14.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

26.8
Genmab A/S
Sector: Healthcare
Industry: Biotechnology
Employees: 2638
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading